病例报告：关于西妥昔单抗致死或接近致死的过敏反应：抗西妥昔单抗 IgE 作为一种有价值的筛选试验。
Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test.
机构信息
CHU de Caen, Service d'Hépato-Gastroentérologie et Nutrition, Caen, France. ; Université de Caen Basse-Normandie, UFR Médecine, Caen, France.
CHU de Caen, Laboratoire d'Immunologie et Immunopathologie, Caen, France.
出版信息
Clin Med Insights Oncol. 2014 Jul 6;8:91-4. doi: 10.4137/CMO.S13897. eCollection 2014.
Abstract
Hypersensitivity reactions are a classic side effect of cetuximab. We report the cases of three patients who developed life-threatening hypersensitivity to cetuximab, which could have been predicted by assessing the concentration of serum anticetuximab immunoglobulin (Ig)E. The anticetuximab IgE concentration could be an interesting test to predict which patients are at risk of experiencing severe hypersensitivity reactions to cetuximab.
摘要
过敏反应是西妥昔单抗的典型副作用。我们报告了三例患者发生危及生命的西妥昔单抗过敏反应的病例，通过评估血清抗西妥昔单抗免疫球蛋白 (Ig)E 浓度可以预测这些反应。抗西妥昔单抗 IgE 浓度可能是一种很有前途的检测方法，可以预测哪些患者有发生严重过敏反应的风险。
相似文献
1
Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test.病例报告：关于西妥昔单抗致死或接近致死的过敏反应：抗西妥昔单抗 IgE 作为一种有价值的筛选试验。
Clin Med Insights Oncol. 2014 Jul 6;8:91-4. doi: 10.4137/CMO.S13897. eCollection 2014.
2
Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test.与西妥昔单抗超敏反应相关的危险因素：以抗西妥昔单抗IgE检测作为筛查试验。
Future Oncol. 2014 Nov;10(14):2133-40. doi: 10.2217/fon.14.153.
3
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.血清抗西妥昔单抗免疫球蛋白E水平在识别西妥昔单抗严重超敏反应高风险患者中的应用
Br J Clin Pharmacol. 2017 Mar;83(3):623-631. doi: 10.1111/bcp.13140. Epub 2016 Oct 24.
4
A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils.一种预测西妥昔单抗诱导的超敏反应的新方法：检测嗜碱性粒细胞上的药物特异性IgE
Cancer Med. 2016 Jun;5(6):1004-12. doi: 10.1002/cam4.658. Epub 2016 Feb 16.
5
Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis.抗西妥昔单抗 IgE ELISA 用于识别发生西妥昔单抗诱导过敏反应的高风险患者。
MAbs. 2011 Jul-Aug;3(4):396-401. doi: 10.4161/mabs.3.4.16293. Epub 2011 Jul 1.
6
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.西妥昔单抗诱导的过敏反应及针对α-1,3-半乳糖的特异性IgE
N Engl J Med. 2008 Mar 13;358(11):1109-17. doi: 10.1056/NEJMoa074943.
7
A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions.西妥昔单抗交叉反应性IgE抗体的回顾性分析及其与严重输注反应的关联。
Cancer Med. 2015 Jan;4(1):36-42. doi: 10.1002/cam4.333. Epub 2014 Oct 9.
8
Anaphylaxis to the carbohydrate side chain alpha-gal.对碳水化合物侧链α-半乳糖的过敏反应。
Immunol Allergy Clin North Am. 2015 May;35(2):247-60. doi: 10.1016/j.iac.2015.01.009. Epub 2015 Mar 6.
9
Alpha-gal is a possible target of IgE-mediated reactivity to antivenom.α-半乳糖是抗蛇毒血清中 IgE 介导反应的可能靶标。
Allergy. 2017 May;72(5):764-771. doi: 10.1111/all.13073. Epub 2016 Nov 21.
10
Alpha-Gal-containing biologics and anaphylaxis.含 Alpha-Gal 的生物制剂与过敏反应。
Allergol Int. 2019 Jul;68(3):296-300. doi: 10.1016/j.alit.2019.04.001. Epub 2019 Apr 30.
引用本文的文献
1
Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.创新的生物治疗药物聚糖结构谱报告和比较指标。
Molecules. 2023 Apr 7;28(8):3304. doi: 10.3390/molecules28083304.
2
Validation of an anti-α-Gal IgE fluoroenzyme-immunoassay for the screening of patients at risk of severe anaphylaxis to cetuximab.验证一种抗 α-Gal IgE 荧光酶免疫分析方法，用于筛选对西妥昔单抗发生严重过敏反应风险的患者。
BMC Cancer. 2023 Jan 9;23(1):32. doi: 10.1186/s12885-023-10501-5.
3
Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection.西妥昔单抗诱导过敏反应的全国性药物警戒数据及使用前瞻性特异性IgE检测的预测模型验证
World Allergy Organ J. 2021 Jun 23;14(7):100553. doi: 10.1016/j.waojou.2021.100553. eCollection 2021 Jul.
4
Anaphylactoid hypersensitivity reaction from intra-arterial cetuximab: Clinical considerations and management.动脉内注射西妥昔单抗引起的类过敏超敏反应：临床考量与处理
SAGE Open Med Case Rep. 2019 Jan 12;7:2050313X18823447. doi: 10.1177/2050313X18823447. eCollection 2019.
5
Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab.血清抗西妥昔单抗免疫球蛋白E水平在识别西妥昔单抗严重超敏反应高风险患者中的应用
Br J Clin Pharmacol. 2017 Mar;83(3):623-631. doi: 10.1111/bcp.13140. Epub 2016 Oct 24.
6
A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils.一种预测西妥昔单抗诱导的超敏反应的新方法：检测嗜碱性粒细胞上的药物特异性IgE
Cancer Med. 2016 Jun;5(6):1004-12. doi: 10.1002/cam4.658. Epub 2016 Feb 16.
本文引用的文献
1
Cetuximab infusion reactions: French pharmacovigilance database analysis.西妥昔单抗输注反应：法国药物警戒数据库分析
J Oncol Pharm Pract. 2013 Jun;19(2):130-7. doi: 10.1177/1078155212457965. Epub 2012 Nov 15.
2
Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.西妥昔单抗超敏输注反应：发生率及危险因素
J Oncol Pharm Pract. 2013 Sep;19(3):222-7. doi: 10.1177/1078155212462440. Epub 2012 Nov 7.
3
Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis.西妥昔单抗的致命性输注反应：免疫球蛋白E介导的过敏反应的作用
J Clin Oncol. 2012 Jan 20;30(3):334; author reply 335. doi: 10.1200/JCO.2011.38.4701. Epub 2011 Dec 12.
4
Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.西妥昔单抗致死性输注反应：对预测性风险因素及更安全患者选择的需求
J Clin Oncol. 2011 Aug 10;29(23):e680-1. doi: 10.1200/JCO.2011.35.5651. Epub 2011 Jun 20.
5
Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis.抗西妥昔单抗 IgE ELISA 用于识别发生西妥昔单抗诱导过敏反应的高风险患者。
MAbs. 2011 Jul-Aug;3(4):396-401. doi: 10.4161/mabs.3.4.16293. Epub 2011 Jul 1.
6
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?常规检测二氢嘧啶脱氢酶以预测氟尿嘧啶相关严重毒性：炒作还是希望？
Clin Colorectal Cancer. 2010 Oct;9(4):224-8. doi: 10.3816/CCC.2010.n.033.
7
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.西妥昔单抗联合化疗治疗晚期非小细胞肺癌患者（FLEX）：一项开放标签的随机III期试验。
Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.
8
Platinum-based chemotherapy plus cetuximab in head and neck cancer.铂类化疗联合西妥昔单抗治疗头颈癌。
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
9
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.西妥昔单抗诱导的过敏反应及针对α-1,3-半乳糖的特异性IgE
N Engl J Med. 2008 Mar 13;358(11):1109-17. doi: 10.1056/NEJMoa074943.
10
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.田纳西州和北卡罗来纳州西妥昔单抗相关输注反应的高发生率及其与特应性病史的关联。
J Clin Oncol. 2007 Aug 20;25(24):3644-8. doi: 10.1200/JCO.2007.11.7812.
Zotero 插件